LUPUS NEPHRITIS (LN)
Clinical trials for LUPUS NEPHRITIS (LN) explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS (LN) trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS (LN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE2 • Sponsor: AbelZeta Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 30, 2026 00:00 UTC
-
New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
Disease control Not yet recruitingThis early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells aim to tame Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat lupus kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Blood traps may reveal lupus kidney treatment success
Diagnosis Not yet recruitingLupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…
Matched conditions: LUPUS NEPHRITIS (LN)
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
A simple blood marker may reveal hidden heart risks in lupus
Knowledge-focused Not yet recruitingThis study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…
Matched conditions: LUPUS NEPHRITIS (LN)
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC